Possible Effect of Autologous Blood Stem Cell Transplantation on Outcome of Acute Myeloid Leukemia in First Relapse
Despite recent progress in the treatment of acute myelogenous leukemia (AML), most patients who achieve complete remission (CR) relapse within 2 years following induction chemotherapy. In some of these latter patients (40%–70%), especially when the duration of first complete remission has been longer than 18 months, a second complete remission may be obtained using different salvage chemotherapeutic regimens. High-dose cytosine arabinoside (HD ARA-C) either alone or in combination with other drugs such as intercalating agents are commonly used in such situations. Once a second CR is achieved, its duration is usually short and does not exceed 1 year in most patients.
KeywordsToxicity Leukemia Oncol Melphalan Resis
Unable to display preview. Download preview PDF.
- 3.Gorin NC, Herve P, Aegerter P, Goldstone A, Linch D, Maraninchi D, Burnett A, Helbig W, Meloni G, Verdonck LF, De Witte T, Rizzoli V, Carella A, Parlier Y, Auvert B, Goldman J (1986) For the Working Party on Autologous Bone Marrow Transplantation of the European Bone Marrow Transplantation Group (EBMTG). Autologous bone marrow transplantation for acute leukemia in remission. Br J Haematol 64: 385–395PubMedCrossRefGoogle Scholar
- 6.Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Buchner T (1987) High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14 [Suppl 1]: 73–77PubMedGoogle Scholar
- 10.Reiffers J, Leverger G, Marit G, Castaigne S, Tilly H, Lepage E, Henon P, Douay L, Troussard X for the France Auto Greffe Group (1989) Haematopoietic reconstitution after autologous blood stem cell transplantation. In: Gale RP, Champlin RE (eds) Bone marrow transplantation: current contro versis. Liss, New York, pp 313–320Google Scholar